20/20 Biolabs, Inc. AIDX 深 沪
已收盘 06-12 16:00:00 美东时间
0.9627
+0.103
+11.94%
华盛通- 最 高0.989
- 今 开0.811
- 成交量 2507.10万股
- 最 低 0.803
- 昨 收 0.86
- 总市值 1021.57万
- 52周最高 50.00
- 市盈率 静 --
- 换手率 236.26%
- 52周最低 0.78
- 委 比 -47.02%
- 总股本 1061.15万
- 历史最高 50.00
- 量 比 356.07
- 振 幅 21.63%
- 历史最低 0.78
- 每 手 1
- 风险率 6.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
20/20 Biolabs' OneTest Multi-Cancer Early Detection Blood Test Selected As Part Of Firefighter Cancer Screening Initiative For State Of Vermont In Partnership With National Diagnostic Services
Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First CohortGAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc.
05-27 20:36
20/20 Biolabs Q1 EPS $(0.28) Misses $(0.10) Estimate, Sales $353.375K Miss $779.000K Estimate
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. This is a 75 percent decrease over losses of $(0.16) per share from the
05-21 04:18
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Maxim Group Initiates Coverage On 20/20 Biolabs with Buy Rating, Announces Price Target of $5
Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a Buy rating and announces Price Target of $5.
05-12 03:46
20/20 BioLabs Says Its OneTest For Cancer Is Now Available Through Evexia Diagnostics Platform
Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine PractitionersMarks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's
04-07 20:39
20/20 Biolabs FY EPS $(0.76) Up From $(1.16) YoY, Sales $2.045M Up From $1.752M YoY
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.76) per share. This is a 34.48 percent increase over losses of $(1.16) per share from the same period last year. The company reported $2.045 million in sales
04-01 05:00
What's Going On With 20/20 Biolabs Stock?
Shares of 20/20 Biolabs, Inc. (NASDAQ: AIDX) are trading lower Tuesday after the company announced that it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare.
03-24 23:07
20/20 BioLabs Partners With ROKIT To Add AI-Driven Kidney Disease Risk And Biomarker Insights To Longevity Platform
Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed TherapiesExpands OneTest for Longevity with Chronic Kidney Disease Risk AssessmentGAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE)
03-24 20:35
20/20 BioLabs Provides Update On Patented PTM Based, Machine Learning Derived Multi-Cancer Early Detection Methodology In Light Of Recent Studies
20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an update on its
03-12 20:45
